OBJECTIVE: To determine if patients with advanced prostate cancer carrying a polymorphism that codes for a more active testosterone transporter have less durable responses to androgen-deprivation therapy (ADT) than patients not carrying this polymorphism. PATIENTS AND METHODS: We previously determined that a polymorphism in SLCO1B3 affects testosterone transport and that those men who have at least one wild-type T allele at the 334 T > G polymorphism in this gene have a shorter survival. We hypothesized that the T allele which increases testosterone transport would be associated with a shorter interval from ADT to androgen independence. We examined the association between this SLCO1B3 polymorphism and time from ADT to androgen independence, ADT to prostate-specific antigen (PSA) nadir and PSA nadir to androgen independence in 68 Caucasian patients with advanced prostate cancer who were treated with ADT with metastatic disease (D2) or biochemical failure with no metastatic disease (D0). RESULTS: When examined separately, patients in the individual stages tended to have a shorter time to androgen independence with the T allele in the D0 (P = 0.11) and D2 (P = 0.18) groups. Combining these groups and stratifying by stage yielded a statistically significant shorter time to androgen independence with the T allele (P = 0.048). CONCLUSION: A polymorphism in a transporter that increases testosterone import is associated with a shorter time to androgen independence in patients with prostate cancer who are treated with ADT.
OBJECTIVE: To determine if patients with advanced prostate cancer carrying a polymorphism that codes for a more active testosterone transporter have less durable responses to androgen-deprivation therapy (ADT) than patients not carrying this polymorphism. PATIENTS AND METHODS: We previously determined that a polymorphism in SLCO1B3 affects testosterone transport and that those men who have at least one wild-type T allele at the 334 T > G polymorphism in this gene have a shorter survival. We hypothesized that the T allele which increases testosterone transport would be associated with a shorter interval from ADT to androgen independence. We examined the association between this SLCO1B3 polymorphism and time from ADT to androgen independence, ADT to prostate-specific antigen (PSA) nadir and PSA nadir to androgen independence in 68 Caucasian patients with advanced prostate cancer who were treated with ADT with metastatic disease (D2) or biochemical failure with no metastatic disease (D0). RESULTS: When examined separately, patients in the individual stages tended to have a shorter time to androgen independence with the T allele in the D0 (P = 0.11) and D2 (P = 0.18) groups. Combining these groups and stratifying by stage yielded a statistically significant shorter time to androgen independence with the T allele (P = 0.048). CONCLUSION: A polymorphism in a transporter that increases testosterone import is associated with a shorter time to androgen independence in patients with prostate cancer who are treated with ADT.
Authors: Matthew R Smith; Fairooz Kabbinavar; Fred Saad; Arif Hussain; Marc C Gittelman; David L Bilhartz; Chris Wynne; Robin Murray; Norman R Zinner; Claude Schulman; Ronald Linnartz; Ming Zheng; Carsten Goessl; Yong-Jiang Hei; Eric J Small; Richard Cook; Celestia S Higano Journal: J Clin Oncol Date: 2005-05-01 Impact factor: 44.544
Authors: Michael Stanbrough; Glenn J Bubley; Kenneth Ross; Todd R Golub; Mark A Rubin; Trevor M Penning; Phillip G Febbo; Steven P Balk Journal: Cancer Res Date: 2006-03-01 Impact factor: 12.701
Authors: Akinobu Hamada; Tristan Sissung; Douglas K Price; Romano Danesi; Cindy H Chau; Nima Sharifi; David Venzon; Kenji Maeda; Keisuke Nagao; Alex Sparreboom; Hiroaki Mitsuya; William L Dahut; William D Figg Journal: Clin Cancer Res Date: 2008-06-01 Impact factor: 12.531
Authors: M A Eisenberger; B A Blumenstein; E D Crawford; G Miller; D G McLeod; P J Loehrer; G Wilding; K Sears; D J Culkin; I M Thompson; A J Bueschen; B A Lowe Journal: N Engl J Med Date: 1998-10-08 Impact factor: 91.245
Authors: Tristan M Sissung; Sarah M Troutman; Tessa J Campbell; Heather M Pressler; Hyeyoung Sung; Susan E Bates; William D Figg Journal: Discov Med Date: 2012-01 Impact factor: 2.970
Authors: Manish Kohli; Shaun M Riska; Douglas W Mahoney; High S Chai; David W Hillman; David N Rider; Brian A Costello; Rui Qin; Jatinder Lamba; Deepak M Sahasrabudhe; James R Cerhan Journal: Mayo Clin Proc Date: 2012-03 Impact factor: 7.616
Authors: Ming Yang; Wanling Xie; Elahe Mostaghel; Mari Nakabayashi; Lillian Werner; Tong Sun; Mark Pomerantz; Matthew Freedman; Robert Ross; Meredith Regan; Nima Sharifi; William Douglas Figg; Steven Balk; Myles Brown; Mary-Ellen Taplin; William K Oh; Gwo-Shu Mary Lee; Philip W Kantoff Journal: J Clin Oncol Date: 2011-05-23 Impact factor: 44.544
Authors: Tristan M Sissung; Caitlin E Baum; C Tyler Kirkland; Rui Gao; Erin R Gardner; William D Figg Journal: Mol Biotechnol Date: 2010-02 Impact factor: 2.695
Authors: Ruben C Hartkoorn; Wai San Kwan; Victoria Shallcross; Ammara Chaikan; Neill Liptrott; Deirdre Egan; Enrique Salcedo Sora; Chloë E James; Sara Gibbons; Pat G Bray; David J Back; Saye H Khoo; Andrew Owen Journal: Pharmacogenet Genomics Date: 2010-02 Impact factor: 2.089
Authors: Tristan M Sissung; Caitlin E Baum; John Deeken; Douglas K Price; Jeanny Aragon-Ching; Seth M Steinberg; William Dahut; Alex Sparreboom; William D Figg Journal: Clin Cancer Res Date: 2008-07-15 Impact factor: 12.531